Start-Ups
Men’s Health Start-Ups Tackle Sexual Stigma
Three early-stage companies, Comphya, ExSeed, and Contraline, shed light on the reproductive issues that many men experience but few discuss openly.
Welcome to MyStrategist, the digital home for MedTech Strategist.
MedTech Strategist, the global medical device industry's most trusted resource, will help you stay ahead of the opportunities and obstacles that are impacting your corporate strategy. We invite you to explore our coverage. Think Strategically. Subscribe Today
Browse Latest IssueStart a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Executive Interviews
Hugo Harrod on How MVM’s Investment Strategy Shaped Its 2024 Medtech Exits
Harrod discusses how MVM built a successful medtech investment strategy and its rationale for investing in Vertos Medical and Gynesonics, two successful exits this year, demonstrating MVM’s optimism about medtech investing overall.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Emerging Markets
Men’s Health Start-Ups Tackle Sexual Stigma
Three early-stage companies, Comphya, ExSeed, and Contraline, shed light on the reproductive issues that many men experience but few discuss openly.